These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11004140)

  • 1. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators.
    Pitt B; Byington RP; Furberg CD; Hunninghake DB; Mancini GB; Miller ME; Riley W
    Circulation; 2000 Sep; 102(13):1503-10. PubMed ID: 11004140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.
    Nissen SE; Tuzcu EM; Libby P; Thompson PD; Ghali M; Garza D; Berman L; Shi H; Buebendorf E; Topol EJ;
    JAMA; 2004 Nov; 292(18):2217-25. PubMed ID: 15536108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of inter-individual blood pressure variability on the progression of atherosclerosis in carotid and coronary arteries: a post hoc analysis of the NORMALISE and PREVENT studies.
    Kim JS; Park S; Yan P; Jeffers BW; Cerezo C
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):82-89. PubMed ID: 27533954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of calcium antagonists on atherosclerosis progression and intima media thickness].
    Zannad F
    Drugs; 2000; 59 Spec No 2():39-46. PubMed ID: 11002857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of the prospective randomized evaluation of the vascular effects of Norvasc (amlodipine) trial: PREVENT.
    Mancini GB
    Can J Cardiol; 2000 Jul; 16 Suppl D():5D-7D. PubMed ID: 10932029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary angiographic changes in patients with cardiac events in the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
    Mancini GB; Pitt B
    Am J Cardiol; 2002 Oct; 90(7):776-8. PubMed ID: 12356398
    [No Abstract]   [Full Text] [Related]  

  • 7. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials.
    Brener SJ; Ivanc TB; Poliszczuk R; Chen M; Tuzcu EM; Hu T; Frid DJ; Nissen SE
    Am Heart J; 2006 Dec; 152(6):1059-63. PubMed ID: 17161053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results and clinical implications of the CAPARES trial.
    Thaulow E; Jorgensen B
    Can J Cardiol; 2000 Jul; 16 Suppl D():8D-11D. PubMed ID: 10932030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term effects of nisoldipine on the progression of coronary atherosclerosis and the occurrence of clinical events: the NICOLE study.
    Dens JA; Desmet WJ; Coussement P; De Scheerder IK; Kostopoulos K; Kerdsinchai P; Supanantaroek C; Piessens JH
    Heart; 2003 Aug; 89(8):887-92. PubMed ID: 12860866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT).
    Byington RP; Miller ME; Herrington D; Riley W; Pitt B; Furberg CD; Hunninghake DB; Mancini GB
    Am J Cardiol; 1997 Oct; 80(8):1087-90. PubMed ID: 9352986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence.
    Mason RP
    Atherosclerosis; 2002 Dec; 165(2):191-9. PubMed ID: 12417269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacoeconomic impact of amlodipine use on coronary artery disease.
    De Portu S; Menditto E; Scalone L; Bustacchini S; Cricelli C; Mantovani LG
    Pharmacol Res; 2006 Aug; 54(2):158-63. PubMed ID: 16814560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
    Miyauchi K; Kojima T; Yokoyama T; Kurata T; Yokoyama K; Kawamura M; Suwa S; Okazaki S; Inoue K; Fujiwara Y; Sumiyoshi M; Tanimoto K; Nakazato Y; Yamagami S; Daida H
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):409-13. PubMed ID: 19763803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium antagonists and atherosclerosis protection in hypertension.
    Hernández RH; Armas-Hernández MJ; Velasco M; Israili ZH; Armas-Padilla MC
    Am J Ther; 2003; 10(6):409-14. PubMed ID: 14624278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
    Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
    Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine.
    Mason RP
    Am J Cardiol; 2001 Nov; 88(10A):2M-6M. PubMed ID: 11705416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post hoc analysis of coronary findings from the prospective randomized evaluation of the vascular effects of the Norvasc trial (PREVENT).
    Mancini GB; Miller ME; Evans GW; Byington R; Furberg CD; Pitt B;
    Am J Cardiol; 2002 Jun; 89(12):1414-6. PubMed ID: 12062738
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms of plaque stabilization for a charged calcium channel blocker in coronary artery disease.
    Mason RP
    Pharmacotherapy; 2001 Sep; 21(9 Pt 2):209S-215S. PubMed ID: 11560191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic benefits of amlodipine treatment in patients with coronary artery disease.
    Casciano R; Doyle JJ; Chen J; Arikian S; Casciano J; Kugel H; Arocho R
    Pharmacoeconomics; 2002; 20(8):553-63. PubMed ID: 12109920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
    Cashin-Hemphill L; Kramsch DM; Azen SP; DeMets D; DeBoer LW; Hwang I; Vailas L; Hirsch LJ; Mack WJ; DeBoer L
    Online J Curr Clin Trials; 1992 Oct; Doc No 26():[9897 words; 83 paragraphs]. PubMed ID: 1343613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.